Spain Administers First Doses of Groundbreaking Gene Therapy for “Butterfly Skin” Disease
In a historic milestone for rare disease treatment in Spain, two children and a young adult with epidermolysis bullosa—commonly known as “butterfly skin” disease—have received the first doses of Vyjuvek, a pioneering gene therapy approved to heal chronic wounds and reduce suffering for patients with this devastating condition. The breakthrough comes after years of advocacy by families and healthcare providers, marking a turning point in the fight against one of the world’s most painful genetic disorders.
Leo, a young boy whose journey has captured national attention, received his first dose of Vyjuvek on April 27, 2026, at Hospital Universitario Virgen del Rocío in Seville. His emotional reaction—shared in an interview with Spanish radio network Onda Cero—highlighted both the hope and relief felt by families who have long awaited effective treatment. “It’s a historic moment,” said his mother, Lidia Osorio, echoing the sentiments of parents across Spain who have watched their children endure daily agony from fragile, blister-prone skin.
Just hours earlier, Adrián Soto, a 22-year-old from Málaga, became the first adult in Andalusia to receive the therapy at Hospital Universitario Costa del Sol. His story, marked by years of painful wound care and limited mobility, underscores the urgent need for treatments like Vyjuvek, which promises to reduce healing time and improve quality of life for patients with dystrophic epidermolysis bullosa (DEB), the most severe form of the disease.
What Is “Butterfly Skin” Disease?
Epidermolysis bullosa (EB) is a group of rare genetic disorders characterized by extreme skin fragility. The term “butterfly skin” comes from the delicate, easily damaged nature of the skin, which can blister or tear from minor friction—even from clothing, walking, or gentle touch. The condition affects approximately 1 in 20,000 births worldwide, with no cure and limited treatment options until recently.
Notice four main types of EB, classified by the layer of skin where blistering occurs:
- Epidermolysis Bullosa Simplex (EBS): The mildest form, affecting the outer layer of skin (epidermis).
- Junctional EB (JEB): Affects the middle layer (dermis), often leading to severe complications.
- Dystrophic EB (DEB): The most severe form, caused by mutations in the COL7A1 gene, which is essential for anchoring the epidermis to the dermis. Without functional collagen VII, the skin tears easily, leading to chronic wounds, scarring, and a high risk of aggressive skin cancer.
- Kindler Syndrome: A rare form involving blistering at multiple skin levels.
For patients with DEB, daily life is a constant battle against pain. Wound care can accept up to 8 hours per day, involving bandage changes, infection prevention, and pain management. Many patients develop complications such as malnutrition, joint contractures, and squamous cell carcinoma, a type of skin cancer that is often fatal in DEB patients.
Vyjuvek: How the Therapy Works
Vyjuvek, developed by Krystal Biotech, is the first topical gene therapy approved for DEB. Unlike traditional treatments that only manage symptoms, Vyjuvek addresses the root cause of the disease by delivering a functional copy of the COL7A1 gene directly to wounded skin cells.
The therapy uses a modified herpes simplex virus (HSV-1) as a vector to carry the gene into skin cells. When applied as a gel to open wounds, Vyjuvek enables the production of collagen VII, which helps anchor the epidermis to the dermis. Clinical trials have shown that treated wounds can remain closed for months after a single application, significantly reducing pain and the need for daily bandage changes.
Leo described the treatment as “a gel that falls in droplets” and confirmed it was painless—a stark contrast to the daily wound care he endures. His first session lasted six hours, during which he and his mother, Lidia, struggled with nerves and anticipation. “We couldn’t believe it until we were there,” Lidia told Onda Cero, reflecting the disbelief and hope felt by families who have waited over a decade for this moment.
A Long Road to Approval in Spain
The arrival of Vyjuvek in Spain follows years of advocacy by patients, families, and organizations like DEBRA Piel de Mariposa, Spain’s leading EB patient association. The therapy received European Union approval in May 2023, but access in Spain was delayed due to funding and logistical challenges. Andalusia became the first region to secure the treatment, with the regional government covering the costs through a special access program for innovative therapies.
Leo’s journey to this moment has been particularly public. In 2025, he addressed the European Parliament, urging Spanish representatives to expedite access to Vyjuvek, which was already available in other EU countries. “I dream of living without so much pain,” he said at the time. “I just want to be a normal kid.” His emotional plea, along with those of other patients, helped accelerate the therapy’s rollout in Spain.
Adrián Soto, the 22-year-old from Málaga, has also been a vocal advocate for EB patients. His daily routine involves hours of wound care, and he has spoken openly about the emotional toll of the disease. “We live against the clock,” he told reporters in February 2026, describing the constant cycle of wound management and pain. His first dose of Vyjuvek, administered on the same day as Leo’s, marks a new chapter for adults with DEB, who often face additional challenges such as mobility limitations and higher cancer risks.
What’s Next for Patients in Spain?
The Andalusian government has confirmed that two children from the Canary Islands will soon receive Vyjuvek, expanding access beyond the region. Hospitals in Córdoba, Seville, Málaga, and Almería have been trained to administer the therapy, with plans to treat additional patients in the coming months. Still, challenges remain, including the high cost of the treatment—estimated at €200,000 to €300,000 per patient annually—and the need for long-term data on its effectiveness.
For families like Leo’s and Adrián’s, the therapy offers more than just medical relief—it represents a chance at a normal life. “Twelve years we’ve waited for this,” Leo said, his voice breaking with emotion during his interview. His mother added that the treatment could mean fewer hospital visits, less pain, and the freedom to participate in activities that most children take for granted.
Despite the progress, advocates emphasize that Vyjuvek is not a cure. While it can heal existing wounds and prevent new ones, it does not address internal complications of EB, such as esophageal strictures or malnutrition. Researchers are continuing to explore other gene therapies and treatments, including systemic approaches that could target the disease throughout the body.
The Global Fight Against Epidermolysis Bullosa
Spain’s rollout of Vyjuvek places it among a growing number of countries offering the therapy, including the United States, where it was approved in 2023, and several EU nations. However, access remains uneven, with many countries still lacking the infrastructure or funding to provide the treatment.
Patient organizations like DEBRA International continue to push for global access, emphasizing that EB is a disease that transcends borders. “Every child with EB deserves the chance to live without constant pain,” said a spokesperson for DEBRA International. “Vyjuvek is a game-changer, but it’s just the beginning.”
For now, Leo, Adrián, and the families who have fought for this moment are celebrating a hard-won victory. Their stories have not only raised awareness of EB but have also highlighted the power of patient advocacy in driving medical innovation. As more patients in Spain and beyond gain access to Vyjuvek, the hope is that their experiences will pave the way for even more breakthroughs in the treatment of rare diseases.
Key Takeaways
- Vyjuvek is the first gene therapy approved for dystrophic epidermolysis bullosa (DEB), a severe form of “butterfly skin” disease.
- Spain has become one of the first countries to administer the therapy, with two children and one adult receiving doses in April 2026.
- The treatment works by delivering a functional copy of the COL7A1 gene to wounded skin, enabling the production of collagen VII, which is missing in DEB patients.
- Clinical trials show that treated wounds can remain closed for months, reducing pain and the need for daily wound care.
- Access to Vyjuvek in Spain was secured after years of advocacy by patients and families, including emotional appeals to the European Parliament.
- While Vyjuvek is a major breakthrough, This proves not a cure, and researchers continue to explore systemic treatments for EB.
FAQ
What is epidermolysis bullosa (EB)?
EB is a group of rare genetic disorders that cause extreme skin fragility. The skin blisters or tears from minor friction, leading to chronic wounds, pain, and complications like infections and skin cancer. There are four main types, with dystrophic EB (DEB) being the most severe.
How does Vyjuvek operate?
Vyjuvek is a topical gene therapy that delivers a functional copy of the COL7A1 gene to wounded skin cells. This gene is responsible for producing collagen VII, a protein that anchors the epidermis to the dermis. Without it, the skin is prone to tearing. The therapy uses a modified herpes simplex virus to carry the gene into skin cells, enabling them to produce collagen VII and heal wounds.
Who is eligible for Vyjuvek?
Vyjuvek is approved for patients with dystrophic epidermolysis bullosa (DEB), the most severe form of EB. It is currently being administered to both children and adults in Spain, with plans to expand access to more patients in the coming months.
What are the side effects of Vyjuvek?
Clinical trials have shown that Vyjuvek is generally well-tolerated. The most common side effects include mild reactions at the application site, such as redness or itching. Because the therapy is applied topically, it does not carry the same risks as systemic gene therapies, which can have more serious side effects.
How much does Vyjuvek cost?
The cost of Vyjuvek is estimated at €200,000 to €300,000 per patient annually. In Spain, the Andalusian government is covering the cost through a special access program for innovative therapies. Patient organizations are advocating for broader funding to ensure all eligible patients can access the treatment.
What’s next for EB research?
While Vyjuvek is a major breakthrough, researchers are continuing to explore other treatments for EB, including systemic gene therapies that could address internal complications of the disease. Clinical trials are also underway for therapies targeting other forms of EB, such as junctional EB.
What Happens Next?
The next steps for Vyjuvek in Spain include expanding access to more patients, particularly in regions like the Canary Islands, where two children are set to receive the therapy soon. The Andalusian government has also committed to monitoring the long-term effectiveness of the treatment and gathering data to support broader adoption.
For patients and families, the focus now shifts to adjusting to life with a treatment that offers real hope. “This is just the beginning,” said Lidia Osorio, Leo’s mother. “We’re excited to see what the future holds.”
As Spain continues to roll out Vyjuvek, the world will be watching to see how this pioneering therapy transforms the lives of those with “butterfly skin” disease. For now, the stories of Leo, Adrián, and others serve as a powerful reminder of the impact of medical innovation—and the importance of ensuring that breakthroughs reach those who need them most.
What are your thoughts on this breakthrough? Share your comments below, and don’t forget to follow World Today Journal for more updates on health and medical innovation.